In renal cell carcinoma (RCC), systemic interleukin-2 (IL-2) treatment activates the immune system, mainly by stimulating natural killer (NK) cells and T cells to kill tumor cells [4]. This evidence concerns the gene IL2 and renal cell carcinoma.